Tag: Paragraph IV certification
180-Day Exclusivity: How Patent Challenges Shape Generic Drug Market Entry
180-day exclusivity under the Hatch-Waxman Act incentivizes generic drug companies to challenge patents, but delays in commercialization can block competition for years. Here's how it works-and why it needs fixing.